C6

Across TCGA pan-cancer cohorts, C6 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated C6 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated C6 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

PDAC, LUAD, and COAD are the cancer types where C6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.682	0.970	.006	30	view →
LUAD	OS	Median	III,IV	0.213	0.677	.003	30	view →
COAD	DFS	Median	All	0.884	1.000	.018	24	view →
GBM	DFS	Median	All	0.265	0.485	.003	15	view →
LSCC	DFS	Median	II,III,IV	0.834	1.000	.004	14	view →
OV	DFS	Median	All	0.938	0.609	.015	8	view →
CCRCC	DFS	Tertile	II,III,IV	0.399	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

C6–PDAC (OS)

Open the PDAC breakdown →